BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 28, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Apogee’s antibody targeting IL-13 has extended half-life compared with other MAbs
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Dermatologic
Apogee’s antibody targeting IL-13 has extended half-life compared with other MAbs
Oct. 17, 2023
No Comments
Apogee Therapeutics Inc. recently presented preclinical data on its lead candidate, APG-777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of atopic dermatitis and asthma.
BioWorld Science
Conferences
Dermatologic
